0001504239 2021-08-01 2022-07-31 0001504239 2022-01-31 0001504239 2022-10-25 0001504239 2022-07-31 0001504239 2021-07-31 0001504239 2020-08-01 2021-07-31 0001504239 us-gaap:PreferredStockMember 2021-07-31 0001504239 us-gaap:CommonStockMember 2021-07-31 0001504239 us-gaap:TreasuryStockMember 2021-07-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001504239 us-gaap:RetainedEarningsMember 2021-07-31 0001504239 us-gaap:PreferredStockMember 2021-08-01 2021-10-31 0001504239 us-gaap:CommonStockMember 2021-08-01 2021-10-31 0001504239 us-gaap:TreasuryStockMember 2021-08-01 2021-10-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2021-08-01 2021-10-31 0001504239 us-gaap:RetainedEarningsMember 2021-08-01 2021-10-31 0001504239 2021-08-01 2021-10-31 0001504239 us-gaap:PreferredStockMember 2021-10-31 0001504239 us-gaap:CommonStockMember 2021-10-31 0001504239 us-gaap:TreasuryStockMember 2021-10-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001504239 us-gaap:RetainedEarningsMember 2021-10-31 0001504239 2021-10-31 0001504239 us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0001504239 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001504239 us-gaap:TreasuryStockMember 2021-11-01 2022-01-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001504239 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001504239 2021-11-01 2022-01-31 0001504239 us-gaap:PreferredStockMember 2022-01-31 0001504239 us-gaap:CommonStockMember 2022-01-31 0001504239 us-gaap:TreasuryStockMember 2022-01-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001504239 us-gaap:RetainedEarningsMember 2022-01-31 0001504239 us-gaap:PreferredStockMember 2022-02-01 2022-04-30 0001504239 us-gaap:CommonStockMember 2022-02-01 2022-04-30 0001504239 us-gaap:TreasuryStockMember 2022-02-01 2022-04-30 0001504239 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0001504239 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0001504239 2022-02-01 2022-04-30 0001504239 us-gaap:PreferredStockMember 2022-04-30 0001504239 us-gaap:CommonStockMember 2022-04-30 0001504239 us-gaap:TreasuryStockMember 2022-04-30 0001504239 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001504239 us-gaap:RetainedEarningsMember 2022-04-30 0001504239 2022-04-30 0001504239 us-gaap:PreferredStockMember 2022-05-01 2022-07-31 0001504239 us-gaap:CommonStockMember 2022-05-01 2022-07-31 0001504239 us-gaap:TreasuryStockMember 2022-05-01 2022-07-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2022-07-31 0001504239 us-gaap:RetainedEarningsMember 2022-05-01 2022-07-31 0001504239 2022-05-01 2022-07-31 0001504239 us-gaap:PreferredStockMember 2022-07-31 0001504239 us-gaap:CommonStockMember 2022-07-31 0001504239 us-gaap:TreasuryStockMember 2022-07-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001504239 us-gaap:RetainedEarningsMember 2022-07-31 0001504239 us-gaap:CommonStockMember 2020-07-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001504239 us-gaap:RetainedEarningsMember 2020-07-31 0001504239 2020-07-31 0001504239 us-gaap:CommonStockMember 2020-08-01 2020-10-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2020-10-31 0001504239 us-gaap:RetainedEarningsMember 2020-08-01 2020-10-31 0001504239 2020-08-01 2020-10-31 0001504239 us-gaap:CommonStockMember 2020-10-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001504239 us-gaap:RetainedEarningsMember 2020-10-31 0001504239 2020-10-31 0001504239 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001504239 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001504239 2020-11-01 2021-01-31 0001504239 us-gaap:CommonStockMember 2021-01-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001504239 us-gaap:RetainedEarningsMember 2021-01-31 0001504239 2021-01-31 0001504239 us-gaap:CommonStockMember 2021-02-01 2021-04-30 0001504239 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2021-04-30 0001504239 us-gaap:RetainedEarningsMember 2021-02-01 2021-04-30 0001504239 2021-02-01 2021-04-30 0001504239 us-gaap:CommonStockMember 2021-04-30 0001504239 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001504239 us-gaap:RetainedEarningsMember 2021-04-30 0001504239 2021-04-30 0001504239 us-gaap:CommonStockMember 2021-05-01 2021-07-31 0001504239 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2021-07-31 0001504239 us-gaap:RetainedEarningsMember 2021-05-01 2021-07-31 0001504239 2021-05-01 2021-07-31 0001504239 2022-06-08 2022-06-08 0001504239 2021-08-02 0001504239 2022-04-15 0001504239 2022-03-26 0001504239 2022-05-11 2022-05-11 iso4217:USD shares iso4217:USD shares pure 0001504239 false --07-31 2022 FY 2820000

P10Y

10-K true 2022-07-31 false 000-56356 POINT OF CARE NANO-TECHNOLOGY INC. NV 27-2830681 109 Ambersweet Way Davenport FL 33897 (732) 723-7395 No No Yes Yes Non-accelerated Filer true false false 940621 K. R. Vancouver, Canada 1212

3198

2917

6115

123466

129581

213335

20240

213335

20240

0.0001

10000000

1000

0.0001

100000000

940621

940

520000

520

120191707

120191187

-120275882

-120212367

-83754

-20240

129581

100000

90000

10000

51800

7500

20180

1534

73515

7500

-63515

-7500

0.08 0.00 787183 940621

940621

940

120191187

-120212367

-20240

1000

-42255

1000

940621

940

120191187

-120254622

-62494

-13795

1000

940621

940

120191187

-120268417

-76289

-520000

-520

520

-5837

1000

940621

940

-520000

-520

120191707

-120274254

-82126

-1628

1000

940621

940

-520000

-520

120191707

-120275882

-83754

940621

940

120191187

-120204867

-12740

940621

940

120191187

-120204867

-12740

940621

940

120191187

-120204867

-12740

940621

940

120191187

-120204867

-12740

-7500

940621

940

120191187

-120212367

-20240

-63515

-7500

1534

-2917

68095

7500

3198

125000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 1</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">COMPANY AND BACKGROUND</td></tr> </table> Point of Care Nano-Technology, Inc. (the “Company”) was incorporated under the laws of the State of Nevada on June 10, 2010, under the name of “Alternative Energy and Environmental Solutions, Inc.” On August 28, 2014, the Company filed an amendment to its Articles of Incorporation changing the name of the Company to “Unique Growing Solutions, Inc.” On March 31, 2015, the Company filed an amendment to its Articles of Incorporation changing the name of the Company to “Point of Care Nano-Technology, Inc.” On February 26, 2015, the Company’s business model was related to using its license, under a certain license agreement (the “License Agreement”) from Lamina Equities Corporation, to first develop and then manufacture saliva-based medical diagnosis products. The Company was not successful and discontinued the majority of its operations by July 31, 2016. Beginning from August 2016, the Company’s plan, which it has since discontinued, was to provide business services and financing to emerging growth entities. On April 15, 2021, the Company accepted the resignations of Dr. Guirguis and Mr. El-Salhy, received a mutual release from both, and appointed Mr. Nicholas DeVito to be Director, Chief Executive Officer and Chief Financial Officer. In addition, for his services to the Company, Mr. DeVito was awarded 1,000 shares of Class A Preferred Stock that grants him 80% voting rights. Also on April 15, 2021 the Company agreed to form a subsidiary and transfer all debts and the License Agreement back to Dr. Guirguis in exchange for 520,000 shares of Common Stock. On August 231, 2021, the Company formed the wholly owned subsidiary, DRG Transfer, Inc. This transaction closed on March 26, 2022. On July 2, 2021, the Company incorporated a wholly owned subsidiary, Duo Sciences, Inc. (“DSI”). On April 11, 2022, the Company, through DSI, acquired an exclusive license to distribute certain intellectual property in animal nutrition and animal supplements from Cedoga Consulting, LLC (“Cedoga”). On April 19, 2022, DSI signed an exclusive sales and promotion agreement with Lucy Pet Products Inc. (“Lucy”) pursuant to which Lucy will manufacture, market and distribute pet products from the Cedoga intellectual property. The Company’s principal executive office location and mailing address is 109 Ambersweet Way, Davenport, FL 33897.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 2</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">CONTROL BY PRINCIPAL OWNERS</td></tr> </table> The directors and executive officers own, directly or indirectly, beneficially and in the aggregate, the majority of the voting power of the outstanding capital stock of the Company. Accordingly, directors, executive officers and their affiliates, if they voted their shares uniformly, would have the ability to control the approval of most corporate actions, including approving significant expenses, increasing the authorized capital and the dissolution, merger, or sale of the Company’s assets.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 3</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">GOING CONCERN</td></tr> </table> These financial statements have been prepared in accordance with generally accepted principles applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for its next twelve months. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern. At July 31, 2022, the Company had not yet achieved profitable operations and had accumulated losses of $120,275,882 and had $3,198 cash on hand. The Company will need to raise additional cash in order to fund ongoing operations over the next 12 month period. These factors which casts substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. No adjustments to the consolidated financial statements have been made as a result of this concern.

-120275882

3198

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 4</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">ACCOUNTING POLICIES</td></tr> </table> The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, the more significant of which are as follows: Consolidation The accompanying consolidated financial statement include the accounts of the Company and its wholly owned subsidiary Duo Sciences Inc. (“DSI”) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available to management. Actual results could differ from those estimates. Financial Instruments Financial instruments consist of cash and accounts payable and accrued liabilities. The carrying amounts of the financial instruments approximate their fair values due to their relatively short-term nature of the underlying terms are consistent with market terms. As of the financial statement date, the Company does not hold any derivate financial instruments. Financial assets and liabilities are measured upon first recognition and reviewed at the financial statement date. Changes in fair value are recognized through profit and loss. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Fair Value Measurements The Company follows FASB Codification topic (“ASC”) 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. The Company has adopted FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Company has not elected the fair value option for any eligible financial instruments. An asset or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities, and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities. Income Taxes The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As the Company has yet to produce positive cash flows from operations, no deferred tax asset or income taxes have been recorded in the financial statements. Comprehensive Income (Loss) The Company adopted FASB ASC 220, Reporting Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting stockholder’s equity that are excluded from net income, such as unrealized gains and losses on investments available for sale, foreign currency translation gains and losses and minimum pension liability. Since inception, the Company has not had any comprehensive income / loss. Net Income (Loss) per Common Share FASB ASC 260, Earnings per share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. Accordingly, although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated net loss per share is the same for bother basic and diluted as both are based on the basic weighted average of common stock outstanding. There were no adjustments required to net income for the period presented in the computation of diluted earnings per share. Segment Reporting FASB ASC 820, “Segments Reporting,” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. The Company currently operates in one principal business segment. Intangible assets Intangible asset are non-monetary identifiable assets, controlled by the Company that will produce future economic benefits, based on reasonable and supportable assumptions about conditions that will exist over the life of the asset. An intangible asset that does not meet these attributes will be recognized as an expense when it is incurred. Intangible assets that do, are capitalized and initially measure at cost. Those with a determinable life will be amortized on a systematic basis over their future economic life. Those with an indefinite useful life shall not be amortized until its useful life is determined to be longer than indefinite. An intangible asset subject to amortization shall be periodically reviewed for impairment. A recoverability test will be performed and, if applicable, unscheduled amortization is considered. The license agreements has been capitalized, recorded at cost and amortized over its estimated useful life of ten years. Amortization has been determined based on a pro rata basis over the expected cash flows. Non-cash transactions The Company follows FASB ASC 845 then recording non-cash transactions. The value of the asset received should be based on the value of the assets surrendered. However, where that value is difficult to determine, then the value could be based on the asset received, provided it is more clearly evident than the value of the asset surrendered. Related Parties The Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Recent Accounting Pronouncements The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position, or cash flow.

Consolidation The accompanying consolidated financial statement include the accounts of the Company and its wholly owned subsidiary Duo Sciences Inc. (“DSI”)

Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available to management. Actual results could differ from those estimates.

Financial Instruments Financial instruments consist of cash and accounts payable and accrued liabilities. The carrying amounts of the financial instruments approximate their fair values due to their relatively short-term nature of the underlying terms are consistent with market terms. As of the financial statement date, the Company does not hold any derivate financial instruments. Financial assets and liabilities are measured upon first recognition and reviewed at the financial statement date. Changes in fair value are recognized through profit and loss. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.

Fair Value Measurements The Company follows FASB Codification topic (“ASC”) 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. The Company has adopted FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Company has not elected the fair value option for any eligible financial instruments. An asset or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities, and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.

Income Taxes The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As the Company has yet to produce positive cash flows from operations, no deferred tax asset or income taxes have been recorded in the financial statements.

Comprehensive Income (Loss) The Company adopted FASB ASC 220, Reporting Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting stockholder’s equity that are excluded from net income, such as unrealized gains and losses on investments available for sale, foreign currency translation gains and losses and minimum pension liability. Since inception, the Company has not had any comprehensive income / loss.

Net Income (Loss) per Common Share FASB ASC 260, Earnings per share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. Accordingly, although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated net loss per share is the same for bother basic and diluted as both are based on the basic weighted average of common stock outstanding. There were no adjustments required to net income for the period presented in the computation of diluted earnings per share.

Segment Reporting FASB ASC 820, “Segments Reporting,” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. The Company currently operates in one principal business segment.

Intangible assets Intangible asset are non-monetary identifiable assets, controlled by the Company that will produce future economic benefits, based on reasonable and supportable assumptions about conditions that will exist over the life of the asset. An intangible asset that does not meet these attributes will be recognized as an expense when it is incurred. Intangible assets that do, are capitalized and initially measure at cost. Those with a determinable life will be amortized on a systematic basis over their future economic life. Those with an indefinite useful life shall not be amortized until its useful life is determined to be longer than indefinite. An intangible asset subject to amortization shall be periodically reviewed for impairment. A recoverability test will be performed and, if applicable, unscheduled amortization is considered. The license agreements has been capitalized, recorded at cost and amortized over its estimated useful life of ten years. Amortization has been determined based on a pro rata basis over the expected cash flows.

Non-cash transactions The Company follows FASB ASC 845 then recording non-cash transactions. The value of the asset received should be based on the value of the assets surrendered. However, where that value is difficult to determine, then the value could be based on the asset received, provided it is more clearly evident than the value of the asset surrendered. Related Parties The Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Recent Accounting Pronouncements The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position, or cash flow.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 5</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">COMMON and PREFERRED STOCK</td></tr> </table> The Company has authorized capital of 100,000,000 shares of common stock, par value of $0.0001 per share, and 10,000,000 shares of “blank check” preferred stock, par value of $0.0001 per share, of which 1,000 shares have been designated as Series A Nonconvertible Preferred Stock (the “Series A Preferred Stock”). During the year ended July 31, 2022, the Company had the following transactions: On June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of the Company’s outstanding common stock. The split was reflected in the public markets on June 9, 2022 and has been given retroactive disclosure in the financial statements. Accordingly, all references to common shares in these financial statements reflect the reverse split. On August 2, 2021, the Company issued 1,000 Series A Preferred Stock to Nicholas DeVito, the Company’s Chief Executive Officer as compensation. The Preferred Stock gives DeVito 80% control of the voting stock of the Company. On April 10, 2022, the Company entered into an agreement under which it agreed to issue 300,000 common shares in order to obtain a license to distribute product (See below). The Company has not yet issued those shares and the obligation to do so is included in the accounts as a $125,000 liability. On April 15, 2022, as part of the Settlement agreement (See below), the Company received into treasury 520,000 shares of common stock (26,000,000 pre reverse split shares). There were no transactions in the Company’s common or preferred stock in the year ended July 31, 2021. There were no warrants or options outstanding as of July 31, 2022.

100000000

0.0001

10000000

0.0001

On June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of the Company’s outstanding common stock.

1000

125000

520000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 6</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">SETTLEMENT AGREEMENT</td></tr> </table> On April 15, 2021, the Company formed a wholly owned subsidiary, DRG Transfer Inc. (“DRG”) and transferred all Company debts relating to the License Agreement business and the License Agreement to DRG to be split off to Dr. Guirguis in exchange for 520,000 share (26,000,000 shares pre reverse split) of the Company’s common stock held by Dr. Guirguis. This transaction closed on March 26, 2022 with Dr. Guirguis giving up and transferring to DRG all the rights, title and interest in the 520,000 shares and DRG contributing all of the legacy business debt and the License Agreement to DRG Transfer, Inc, a Nevada corporation, and transferring all of the outstanding capital stock in DRG Transfer, Inc. to Dr. Guirguis.

520000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 7</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">LICENSE PURCHASED and INTANGIBLE ASSETS</td></tr> </table> On April 11, 2022, the Company, through its wholly owned subsidiary DSI, acquired an exclusive license to distribute in the USA, Canada and Mexico, certain intellectual property in animal nutrition and animal supplements from Cedoga Consulting, LLC. The Company receives 10% of all licensing fees due to Cedoga in exchange for 300,000 post reverse split shares of common stock of the Company. Under the terms of the agreement, the Company will pay royalties from sub-licensing on the following basis: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">90% of net royalties for sale and initial payments up to $100,000,000 per calendar year.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">95% of net royalties received for continuing sales above $100,000,000 per calendar year.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">90% of any lump up-front payment sub-licensing fees.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Option to purchase 200,000 shares of the Company’s common stock when net sales exceed $100,000,000.</td></tr> </table> The license value has been based on the expected discounted cash flows the license will generate to the Company over its estimated 10 year life. The Company’s common shares are very lightly traded and management determined that their market value are not reliable as a determinant of value for this transaction. Schedule of License Purchased <table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLicensePurchasedAndIntangibleAssetsDetailsAbstract_zrk46zjKKN02" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - LICENSE PURCHASED and INTANGIBLE ASSETS (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"/><td/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_492_20210801__20220731_zXAvHo6NfWi9" style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_496_20200801__20210731_z25PjuHD3Hr" style="white-space: nowrap; text-align: center"/><td/></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="6" style="white-space: nowrap; text-align: center">As of July 31</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_ecustom--LicenseFeeToBePaidInCommonShares_zXd1RxVZ01F6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: justify">License</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">125,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_zwFFw1VkCaRe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,534</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_zaR9uUbaUKW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">123,466</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Schedule of License Purchased

<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLicensePurchasedAndIntangibleAssetsDetailsAbstract_zrk46zjKKN02" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - LICENSE PURCHASED and INTANGIBLE ASSETS (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"/><td/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_492_20210801__20220731_zXAvHo6NfWi9" style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_496_20200801__20210731_z25PjuHD3Hr" style="white-space: nowrap; text-align: center"/><td/></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="6" style="white-space: nowrap; text-align: center">As of July 31</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_ecustom--LicenseFeeToBePaidInCommonShares_zXd1RxVZ01F6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: justify">License</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">125,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_zwFFw1VkCaRe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,534</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_zaR9uUbaUKW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">123,466</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 125000

1534

123466

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 8</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">EXCLUSIVE SALES SUB-LICENSING AGREEMENT</td></tr> </table> On April 19, 2022, DSI signed an exclusive sales and promotion sub-licensing agreement with Lucy Pet Products Inc. (“Lucy”) pursuant to which Lucy will manufacture, market and distribute pet products derived from the Cedoga intellectual property. The terms of the sub-licensing agreement are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Lucy will pay the Company a one-time sub-license fee of $100,000 on execution of the sub-licensing agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Lucy will pay the Company royalties of 5% of Net Revenue, calculated and payable quarterly. Net Revenue is defined as total revenue less direct cost of materials, manufacturing, packaging and delivery expenses and less excise, sales or similar taxes.</td></tr> </table> On May 11, 2022, the Company received the first payment from Lucy of $100,000 under its sub-license agreement with Lucy and remitted $90,000 to Cedoga according to the Cedoga license agreement.

100000

90000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 9</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">INCOME TAXES</td></tr> </table> As at July 31, 2022, no tax benefit has been recorded with respect to the net operating loss in the financial statements as the management of the Company believes that the realization of the Company’s net deferred tax assets would not be considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are offset by the full valuation allowance. The Company has a net operating loss carryforward of approximately $1,813,968. Income tax recovery differs from that which would be expected from applying the effective tax rates to the net loss for the years ended July 31, 2022 and 2021 as follows: Schedule of Income tax Reconciliation <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureIncomeTaxesDetailsAbstract_z558DKDh8hi6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"/><td/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_49B_20210801__20220731_zXy0qYEv26da" style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_496_20200801__20210731_z802Wi8gsWDd" style="white-space: nowrap; text-align: center"/><td/></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="6" style="white-space: nowrap; text-align: center">Year Ended July 31</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_zsUgwCopqghd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Net loss for the year</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(63,515</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(7,500</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zUyVNEviRxE9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Statutory and effective tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.46</td><td style="white-space: nowrap; text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.46</td><td style="white-space: nowrap; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzilS_zYSiwTTTzWqf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected income tax recovery</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(16,162</td><td style="white-space: nowrap; text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,909</td><td style="white-space: nowrap; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_maITEBzilS_zXjDWKMzutZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Tax benefit deferred</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,162</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,909</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzilS_zhY78GRNyVJc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income taxes recorded</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Schedule of Deferred Tax Assets <table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--DisclosureIncomeTaxesDetails2Abstract_zmJb5jOIkgM" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"/><td/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_498_20210801__20220731_zU84TX7M39hg" style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_498_20200801__20210731_z20efNsAc3wi" style="white-space: nowrap; text-align: center"/><td/></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="6" style="white-space: nowrap; text-align: center">Year Ended July 31</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iE_zJ1ezL6OGpX2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Tax losses carried forward</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,814,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,750,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_z7NGl6Gw5qih" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Statutory and effective tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.46</td><td style="white-space: nowrap; text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.46</td><td style="white-space: nowrap; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_iE_maDTANzWY4_zTcLQyvxips3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Deferred tax asset</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">462,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">446,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_di_msDTANzWY4_zGrn81eKi7Fk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(462,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(446,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iE_mtDTANzWY4_zw5GXQIBG8s3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company’s income tax filings are subject to audit by various taxing authorities. The Company’s open audit periods include from Inception (June 10, 2010) to the current tax year.

1813968

Income tax recovery differs from that which would be expected from applying the effective tax rates to the net loss for the years ended July 31, 2022 and 2021 as follows: Schedule of Income tax Reconciliation

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureIncomeTaxesDetailsAbstract_z558DKDh8hi6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"/><td/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_49B_20210801__20220731_zXy0qYEv26da" style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_496_20200801__20210731_z802Wi8gsWDd" style="white-space: nowrap; text-align: center"/><td/></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="6" style="white-space: nowrap; text-align: center">Year Ended July 31</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_zsUgwCopqghd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Net loss for the year</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(63,515</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(7,500</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zUyVNEviRxE9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Statutory and effective tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.46</td><td style="white-space: nowrap; text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.46</td><td style="white-space: nowrap; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzilS_zYSiwTTTzWqf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected income tax recovery</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(16,162</td><td style="white-space: nowrap; text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,909</td><td style="white-space: nowrap; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_maITEBzilS_zXjDWKMzutZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Tax benefit deferred</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,162</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,909</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzilS_zhY78GRNyVJc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income taxes recorded</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

-63515

-7500

0.2546

-16162

-1909

-16162

-1909

Schedule of Deferred Tax Assets

<table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--DisclosureIncomeTaxesDetails2Abstract_zmJb5jOIkgM" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"/><td/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_498_20210801__20220731_zU84TX7M39hg" style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_498_20200801__20210731_z20efNsAc3wi" style="white-space: nowrap; text-align: center"/><td/></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="6" style="white-space: nowrap; text-align: center">Year Ended July 31</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iE_zJ1ezL6OGpX2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Tax losses carried forward</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,814,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,750,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_z7NGl6Gw5qih" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Statutory and effective tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.46</td><td style="white-space: nowrap; text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.46</td><td style="white-space: nowrap; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_iE_maDTANzWY4_zTcLQyvxips3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Deferred tax asset</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">462,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">446,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_di_msDTANzWY4_zGrn81eKi7Fk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(462,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(446,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iE_mtDTANzWY4_zw5GXQIBG8s3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1814000

1750000

0.2546

462000

446000

462000

446000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">Note 10</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify">SUBSEQUENT EVENTS</td></tr> </table> On August 24, 2022, the Company completed a financing with an investor for $10,000 in exchange for Units consisting of (i) one share of common stock, par value $0.001 per share for $0.10 per share, (ii) one LOI option to purchase one share of common stock for $0.20 per share upon the Company signing a letter of intent with a third party and (iii) one Agreement option to purchase one share of common stock for $0.30 per share upon the Company signing an agreement with a third party.